Logo

COSM

Cosmos Health Inc.

COSM

Cosmos Health Inc. • NASDAQ
$0.64 ▲ 1.31% (+0.01)
Market Cap $17.47 M
52w High $1.32
52w Low $0.28
Dividend Yield 0%
P/E -0.83
Volume 250.33K
Outstanding Shares 27.23M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $17.11M ▲ $4.421M ▲ $-5.353M ▼ -31.284% ▼ $-0.17 ▼ $-4.306M ▼
Q2-2025 $14.746M ▲ $3.809M ▲ $-2.828M ▼ -19.179% ▼ $-0.098 ▼ $-1.922M ▼
Q1-2025 $13.713M ▼ $2.883M ▼ $-818.097K ▲ -5.966% ▲ $-0.034 ▲ $-310.551K ▲
Q4-2024 $14.224M ▲ $9.97M ▲ $-9.543M ▼ -67.091% ▼ $-0.5 ▼ $-8.378M ▼
Q3-2024 $12.411M $3.447M $-2.183M -17.585% $-0.45 $-1.697M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $922.619K ▲ $69.493M ▲ $46.358M ▲ $23.135M ▼
Q2-2025 $685.769K ▼ $61.836M ▲ $35.604M ▲ $26.232M ▲
Q1-2025 $768.159K ▲ $57.192M ▲ $31.24M ▲ $25.952M ▲
Q4-2024 $336.253K ▼ $54.312M ▼ $29.779M ▲ $24.533M ▼
Q3-2024 $3.338M $64.52M $29.543M $34.977M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-5.353M ▼ $-3.971M ▼ $-1.01M ▼ $8.708M ▲ $3.978M ▲ $-3.984M ▼
Q2-2025 $-2.828M ▼ $-1.21M ▼ $71.82K ▲ $1.604M ▲ $-87.378K ▼ $-1.328M ▼
Q1-2025 $-818.097K ▲ $-186.316K ▲ $-7.069K ▲ $560.862K ▼ $427.776K ▲ $-200.119K ▲
Q4-2024 $-9.543M ▼ $-3.834M ▼ $-1.005M ▼ $1.62M ▼ $-3M ▼ $-4.755M ▼
Q3-2024 $-2.183M $739.774K $-35.433K $2.68M $2.971M $511.007K

Revenue by Products

Product Q4-2023Q1-2025Q2-2025Q3-2025
Nutraceuticals and Pharmaceuticals
Nutraceuticals and Pharmaceuticals
 $0 ▲$0 ▲$0 ▲$0 ▲
Pharma manufacturing
Pharma manufacturing
 $0 ▲$0 ▲$0 ▲$0 ▲
Wholesale
Wholesale
 $0 ▲$0 ▲$30.00M ▲$10.00M ▼

Five-Year Company Overview

Income Statement

Income Statement Cosmos Health’s income statement shows a very small business that is still losing money. Revenue has barely grown over the past several years and remains low, while profitability has not yet appeared. Gross profit is thin, operating results are negative, and the company has reported net losses every year in the period shown. The earnings per share swings look dramatic, but that’s largely driven by reverse stock splits rather than big operational changes. Overall, this is still an early-stage, subscale operation trying to build up its revenue base and move toward break-even, but it is not there yet.

Balance Sheet

Balance Sheet The balance sheet is modest in size, with limited assets and only a small cash cushion. Debt is present but not excessive relative to the small asset base, suggesting some leverage but not a heavily indebted profile. Equity turned from essentially negligible to somewhat positive, which likely reflects capital raises rather than internally generated profits. The structure looks fragile: there is not a lot of buffer to absorb shocks, so the company’s financial health depends heavily on continued access to funding and on executing its growth plans.

Cash Flow

Cash Flow Cash flow from operations has been consistently negative, indicating that the core business consumes cash rather than generating it. Free cash flow is also negative, and investment spending has been minimal, which is typical for a company trying to conserve cash. This pattern means the business is reliant on outside financing—either debt, equity issuance, or other arrangements—to keep funding operations and growth initiatives. Until operating cash flow turns positive, liquidity and financing risk remain central concerns.

Competitive Edge

Competitive Edge Cosmos Health is trying to carve out a niche by being vertically integrated—owning brands, manufacturing, and distribution—and by focusing on higher-margin nutraceuticals rather than low-margin wholesale drugs. Its own brands and upgraded manufacturing facilities provide some differentiation, and the move to U.S.-based production to avoid tariffs and supply disruptions is strategically sensible. However, the markets it operates in—generic drugs, nutraceuticals, and telehealth—are highly competitive and dominated by larger, better-capitalized players. The company’s small scale, limited financial resources, and relatively short operating track record in these newer areas mean its competitive moat is still emerging rather than firmly established. The digital asset strategy (investing in Ethereum) is unusual for a healthcare company and adds financial volatility and strategic complexity on top of an already challenging competitive landscape.

Innovation and R&D

Innovation and R&D Innovation is a clear focus and arguably the main attraction of the story. Cosmos is investing in nanotechnology-based delivery systems for supplements, aiming to make products that are better absorbed and more effective, and doing so with cleaner, more sustainable manufacturing methods. Its AI-driven drug repurposing platform is designed to find new uses for existing drugs, potentially speeding development and opening doors in areas like oncology and neurology. The obesity treatment candidate, CCX0722, is a notable near-term project that, if successfully developed and commercialized, could address a very large market. That said, all of these initiatives carry meaningful scientific, regulatory, and commercial risk: timelines can slip, clinical results may disappoint, and market uptake is uncertain. The innovation pipeline is rich on paper but still needs to prove itself in real-world results and revenue.

Summary

Cosmos Health combines a small, loss-making financial base with an ambitious, innovation-heavy strategy. The company is trying to move up the value chain—away from low-margin distribution and toward proprietary brands, advanced nutraceuticals, and novel therapies—while using vertical integration and U.S. manufacturing to improve margins and reliability. At the same time, it operates with limited cash, persistent negative cash flow, and a history of reverse splits, all of which point to a high dependence on external financing and heightened dilution risk. The innovation portfolio in nanotechnology, AI-driven drug discovery, and obesity treatment is promising but still largely unproven. Overall, this is a high-risk, early-stage profile where future outcomes will depend heavily on execution, regulatory progress, successful product launches, and prudent management of financial resources.

NEWS

November 17, 2025 · 9:15 AM UTC

Cosmos Health Reports Record Q3 2025 Results with All-Time High Revenue, Gross Profit and Gross Margin; Revenue Up 38% to $17.1M, Gross Profit Up 116% to $2.6M, Adjusted EBITDA Up 74%, Cash Position Up to $4.63M from $0.66M

Read more

October 31, 2025 · 10:45 AM UTC

Cosmos Health Enters New Nanotechnology R&D Program to Develop Next-Generation Nutraceutical Formulas with Enhanced Phytochemical Efficacy

Read more

October 21, 2025 · 12:10 PM UTC

Cosmos Health Expands Its Ethereum Holdings With an Additional $200,000 Purchase Under Its $300 Million Digital Assets Facility; Total Investment Now Reaches $2 Million

Read more

October 13, 2025 · 2:05 PM UTC

Cosmos Health Purchases an Additional $300,000 in Ethereum Under Its $300 Million Digital Assets Facility; Total Investment Reaches $1.8 Million

Read more

October 10, 2025 · 8:00 AM UTC

Cosmos Health Purchases an Additional $500,000 in Ethereum Pursuant to its $300 Million Digital Assets Facility

Read more